alexa Study of Methyl Dopa Versus Labetalol in Management of Preeclampsia and Gestational Hypertension | Open Access Journals
ISSN: 2161-0932
Gynecology & Obstetrics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Study of Methyl Dopa Versus Labetalol in Management of Preeclampsia and Gestational Hypertension

Dharwadkar MN1, Kanakamma MK1, Dharwadkar SN2*, Rajagopal K1, Gopakumar C3, Divya James Fenn J4 and Balachandar V3,5

1Department of Obstetrics and Gynaecology, Yenepoya Medical College and teaching Hospital, Yenepoya University, Deralakatte, Mangalore, Karnataka 575022, India

2Department of Zoology, K.L.E’s. S. Nijalingappa College, KLE Medical University (Health), Bangalore, Karnataka 560010, India

3Department of Human Genetics Molecular Biology, Bharathiar University, Coimbatore, India

4Post Graduate Student, Department of Obstetrics and Gynaecology, Sree Balaji Medical College and Hospital, Chennai 600044, Tamil Nadu, India

5Human Molecular Genetics Laboratory, Department of Zoology, Bharathiar University, Coimbatore, India

*Corresponding Author:
Dharwadkar SN
Department of Zoology
K.L.E′s. S. Nijalingappa College
KLE Medical University (Health)
Bangalore, Karnataka 560010, India
Tel: +91 998612290
E-mail: [email protected]

Received date: May 27, 2014; Accepted date: September 12, 2014; Published date: September 15, 2014

Citation: Dharwadkar MN, Kanakamma MK, Dharwadkar SN, Rajagopal K, Gopakumar C, et al. (2014) Study of Methyl Dopa Versus Labetalol in Management of Preeclampsia and Gestational Hypertension. Gynecol Obstet (Sunnyvale) 4:242 doi:10.4172/2161-0932.1000242

Copyright: © 2014 Dharwadkar MN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Gynecology & Obstetrics

Abstract

Objective: To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH). Methods: Eighty patients with PIH were randomly allocated to receive either labetalol (group A) or methyldopa (group B). Administration of drugs with respect to Age, Gravid Status, Blood Pressure, Urine albumin Levels, Side Effects, Drug dosage, Additional Treatment, Prolongation of Pregnancy, New born Screening Test (NST), mode of termination, Indication of caesarean section, Perinatal safety and APGAR scores were studied. The statistical level of significance was taken at P<0.05. Results: A labetalol has been very effective in control as well as earlier onset of action in patients with methyl dopa. With effective control of blood pressure, prevention of eclampsia and the pregnancy can be prolonged to achieve fetal maturity. Labetalol has lesser side effects when compared to methyldopa. Labetalol is not associated with adverse fetal effects in the immediate and late neonatal period. The chances of spontaneous onset of labor were greater in the labetalol group when compared to methyldopa group. Though there was no difference in the groups with regard to obstetric intervention. At clinically effective doses, both the drugs were found to be safe for the neonate. Conclusions: Labetalol is safer, quicker in achieving adequate control of blood pressure with considerable prolongation of the duration of pregnancy with fewer side effects on the mother as well as the neonate when used in the management hypertensive disorders of pregnancy.

Keywords

Antihypertensive drugs; Pregnancy; Pre eclampsia; Hypertension; Management

Introduction

Hypertension is the most common medical problem encountered during pregnancy [1]. Hypertensive disorders seem to complicate approximately 10% of pregnancies and are important causes of maternal and fetal morbidity and mortality [2]. Validation studies of the reporting of hypertension in pregnancy have been conducted in Australia, Canada, Denmark, Norway, Sweden and the USA, with consistent findings about the reliability of each country’s ascertainment methods [3,4]. In India the incidence of hypertension occurs in well over 6% to 8% of all pregnancies [5-7]. In addition to the risk they present to the pregnancy, hypertensive disorders of pregnancy have been linked to future high blood pressure and cardiovascular disease in women [8-11].

The population prevalence of factors associated with increased and decreased risk of pregnancy hypertension and pre-eclampsia has changed over time, but the impact of these changes is unknown. Hypertension complicates up to 10% of all pregnancies and is associated with increased risk of adverse fetal, neonatal and maternal outcomes, including preterm birth, intrauterine growth restriction, multiple births, diabetes, chronic hypertension, perinatal death, acute renal or hepatic failure, antepartum haemorrhage, postpartum haemorrhage and maternal death [12-17]. Decreased risk of pregnancy hypertension and pre-eclampsia has been associated with placenta praevia, smoking (although smoking may only be protective in the non-obese), summer births, low-dose aspirin and calcium supplementation in high-risk women, treatment of gestational diabetes and use of antihypertensive medications [14,15]. As the majority of cases of pregnancy hypertension and preeclampsia occur at term, increasing rates of early elective delivery may reduce their frequency [18,19]. Trends in pregnancy hypertension and pre-eclampsia are the result of the effects of changes in all these factors.

Identification of this specific risk made the control of acutely raised blood pressure as central point for women with severe hypertension, particularly that of pre-eclampsia. During this period the maternal and foetal conditions are monitored along with control of hypertension by antihypertensive drugs. The risk of developing severe hypertension is reduced to half by using antihypertensive medications [20]. Severe hypertension is treated to prevent severe maternal complications [21].

A wide spectrum of antihypertensive agents represents the key of successful pregnancy hypertension treatment and opportunity of choice, in accordance with indications and availability of drugs provided by drug tendering [22-24]. Methyldopa was most commonly used for treatment of hypertension during pregnancy based on its effectiveness and safety for both mother and foetus as an antihypertensive drugbut it takes longer time to act and also less efficacious as hypotensive drug. It is still the most commonly used drug for long term control of blood pressure in pregnancy. Methyldopa is a centrally acting adrenergic antagonist that acts by stimulation of the central alpha 2 receptors, leading to a decrease in sympathetic nerve activity with resultant arterial dilatation and reduction in BP. Long term follow up data of 7 years shows no detrimental effects to the off springs in the Methyldopa treated group. At high doses the sedative and depressant effects of methyldopa are marked. Methyldopa should not be used if there is a substantial risk of maternal depression when a beta-blocking agent or calcium antagonist may be more suitable.

Labetalol gives better control of blood pressure compared to other anti-hypertensive agents [25]. Labetalol is a combined alpha- and beta-blocker and has the advantage over other beta blockers due to its additional arteriolar vasodilator action that helps to lower peripheral vascular resistance with little or no decrease in cardiac output. Advantage of labetalol is that, it is available as both injectable and oral and time of onset of action is earlier than methyldopa [25]. .However now, it is known that b-blockers cross the placental barrier and may cause foetalbradycardia. Experimental evidence also suggests that b-blocking agents reduce foetal tolerance to hypoxic stress. Out of the 80 patients in our study, 1 patient’s NST at admission was non-reactive hence it was not included how-ever the rest 79 patients non-stress tests taken after 48 hours of drug administration for both the groups were reactive depicting that either one of the drugs do not have any adverse effect on the foetus.

Materials and Methods

Subject recruitment

A prospective randomized study was carried out in 80 pregnant women from 2011-2013 in the Department of Obstetrics and Gynaecology, Yenepoya Medical College and Hospital, Mangalore. All pregnant women attending the antenatal clinic were screened for and hypertensive pregnant women were included in the study after obtaining informed consent. The study was approved by the institutional ethics committee of the hospital. The criteria for diagnosis and classification of the hypertensive disorder of pregnancy will be obtained according to the National High Blood Pressure Education Program Working Group (NHBPEPWG). Medical and obstetric history taking and physical examination were performed at the time of initial recruitment. Serial BP recordings were measured twice in a day 12 hours apart from the time of administration of the drugs to patients who are divided into two groups based on the drug they receive. The duration required for the drug to act was then calculated along with assessment of other parameters such as side effects, prolongation of the duration of the pregnancy and number of additional drugs required. Neonatal morbidity in terms of birth weight, 5 minute APGAR scores, NICU stay and indication of the stay were all taken into account.

The pregnant women with BP of more than or equal to 140/90 with or without proteinuria were included irrespective of their gravid status, gestational age and maternal age were included in our study.Selection of patients was restricted to those who,Non- consenting patients, patient coming for the first time during labour, patientwith eclampsia, platelet count <100000/mm3, HELLP syndrome, pulmonary edema, recurrent pregnancy loss and also known case of diabetes mellitus, renal disease, cardiac disease, haematological disorders hydatidi form mole, multiple gestations.

A total number of 80 patients attending the ante-natal clinic were included after diagnosing them with hypertension or pre-eclampsia ward. Among them 40 of subjects with preeclampsia and the others 40 with gestational hypertension. These patients were randomly assigned with either Labetalol (Group A) or Methyldopa (Group B) in groups of 20 cases each. A detailed history, examinationand investigated in detail. BP was recorded using mercury sphygmomanometer with patient in left lateral recumbent position after 20 min rest. Conventional mercury sphygmomanometer was used for BP measurement and phases I and V Koratok off sounds were respectively used to define systolicand diastolic BP.

Patients close to term were followed up in the hospital whereas others were discharged after 7-10 days provided they had good control of BP, and did not show significant proteinuria or gross intra uterine growth retardation. On discharge, patients were advised to take the dose titrated for them based on their assessment during their hospital stay and were advised to come for weekly follow up and get re-admitted if BP control was unsatisfactory.

Patients whose BP remained uncontrolled inspite of therapy in both the groups were closely monitored in the hospital and attempt was made to continue the pregnancy with additional drugs such as nifedepine in varying doses or phenobarbital or magnesium sulphate were given. Prophylactic corticosteroids were given in patients who were less than 36 weeks period of gestation to better the neonatal outcome especially in those patients in whom the pregnancy had to be terminated early by induction of labour, and/or caesarean section done. The efficacy was measured in terms of the fall in both systolic and diastolic BP by 48 hours as well as 5th day of the drug administration and the results were tabulated.

Results

A total of 80 patients were included in this study by a prospective randomized trial 40 of them with pre eclampsia and 40 of them with gestational hypertension. Pre-eclamptic 40 were divided into two groups of 20 each and given labetalol & methyl dopa, similarly 40 patients of gestational hypertension were divided in two groups of 20 each and labetalol and methyl dopa were administered.

The mean birth weight in the labetalol group with gestational hypertension and pre-eclampsia were 2.6 and 2.56 while the mean birth weight in the methyl dopa group hypertension and pre-eclampsia was 2.5 and 2.635 respectively showing that there wasn’t a significant difference in either drug groups. The mean 5 minute APGAR scores for labetalol group with hypertension 8 and pre-eclampsia 7.55. The methyldopa group for hypertension and pre-eclampsia were 7.6 and 7.85 respectively. In the labetalol group there were 13 neonates with hyperbilirubinemia, 4 with Respiratory Distress Syndrome (RDS) and 2 suffered from Meconium Aspiration Syndrome (MAS). In the methyldopa group similar numbers were seen 10 hyperbilirubinemia, 5 RDS and 2 with MAS. There was no statistically significant in the neonatal morbidity between the two drug groups.

The mean difference in the fall with labetalol of the systolic/diastolic BP by 48 hours was 9/6.7mmHg and by the 5th day it was 11.9/8.7 mmHg as compared to methyl dopa being 3.5/3.6 mmHg in the first 48 hours followed by 8.3/5.9 in the hypertension patients. Similar numbers were seen in the pre-eclampsia patients, 48 hour fall 8.7/7.2 and 5th day fall of 16.8/13.2 with labetalol as compared 48 hour fall of 1.5/2.2 mmHg and 5th fall of 8.3/6.6mmHg of methyl dopa patients clearly stating that labetalol is a better drug in effectively reducing the BP of the patients and then maintain optimal BP levels.

In the present study the mean age of patients who are in Preeclampsia receiving the drugs under study shows that there is no statistically significant difference in the age distribution of the patients (p-0.567) and patients with Gestational hypertension had statistically significant difference between the drugs when it comes to the age parameter (p-0.211) (Table 1). There is no statistically significant difference between both the drug groups with respect to the gravid status of the patients with Pre-eclampsia and gestational hypertension (Table 2). No statistically significant differences were found between both the drug groups (Booked or Unbooked (B/U)) (Table 3). Table 4 depicts the following two graphs unequivocally depict that labetalol has a better effect on control of BP added by quick onset of action which is not the case with methyl dopa. Further-more the maintenance of optimal BP levels were seen through-out the course of therapy. Table 5 Describes the total dose required per day was more with methyl dopa and labetalol required comparatively lesser dosage as evidenced by the p-value in both the groups. Labetalol shows a statistically significant p-value of 0.005 in gestational hypertension patients with respect to prolongation of pregnancy how-ever it is not reflected in the patients with pre-eclampsia (Table 6). There was no significant difference in birth weight of the neonates in either drug groups (Table 7). The APGAR scores of the neonates at 5 min were in the same range in both labetalol and methyl dopa with no significant statistical difference (Table 8). There is a small but statistically insignificant increase in the NICU stay with methyl dopa (Table 9). Table 10 shows the neonatal morbidity of pregnancy, the various causes of morbidity were hyperbilirubinemia, respiratory distress syndrome, meconeum aspiration syndrome IUGR and Pre-maturity however when compared in either drug groups there was no statistical significance.

  Particulars N Mean ± SD t df p Value
AGE Preeclampsia Labetalol in Pre-Eclampsia 20 26.65± 3.731 0.577 38 0.567
Methyl-dopa in pre-eclampsia 20 25.95± 3.94      
Gestational Hypertension Labetalol in GHTN 20 29.9± 3.81 1.271 38 0.211
Methyl-Dopa  In Ghtn 20 28.05± 5.276      

Table 1: Depicts the mean age of patients receiving the drugs.

  GROUP Total GROUP Total
Labetalol in gestational hypertension Methyl-dopa in gestational hypertension Labetalol in pre-eclampsia Methyl-Dopa in Pre-Eclampsia
Obstetric
Score /
Gravid
Status
G2P1L1 Count 8 6 14 0 6 6
% within OS 57.1% 42.9% 100.0% 0.0% 100.0% 100.0%
% within GROUP 40.0% 30.0% 35.0% 0.0% 30.0% 15.0%
G2P1P1 Count NA NA NA 2 0 2
% within OS NA NA NA 100.0% 0.0% 100.0%
% within GROUP NA NA NA 10.0% 0.0% 5.0%
G5P4L3 Count NA NA NA 0 1 1
% within OS NA NA NA 0.0% 100.0% 100.0%
% within GROUP NA NA NA 0.0% 5.0% 2.5%
G3P2L2 Count 5 6 11 4 3 7
% within OS 45.5% 54.5% 100.0% 57.1% 42.9% 100.0%
% within GROUP 25.0% 30.0% 27.5% 20.0% 15.0% 17.5%
G4P3L3 Count 1 2 3 2 1 3
% within OS 33.3% 66.7% 100.0% 66.7% 33.3% 100.0%
% within GROUP 5.0% 10.0% 7.5% 10.0% 5.0% 7.5%
G5P4L4 Count 2 1 3 NA NA NA
% within OS 66.7% 33.3% 100.0% NA NA NA
% within GROUP 10.0% 5.0% 7.5% NA NA NA
G6P5L4 Count 1 0 1 NA NA NA
% within OS 100.0% 0.0% 100.0% NA NA NA
% within GROUP 5.0% 0.0% 2.5% NA NA NA
G6P5L5 Count 0 1 1 NA NA NA
% within OS 0.0% 100.0% 100.0% NA NA NA
% within GROUP 0.0% 5.0% 2.5% NA NA NA
Primi Count 3 4 7 12 9 21
% within OS 42.9% 57.1% 100.0% 57.1% 42.9% 100.0%
% within GROUP 15.0% 20.0% 17.5% 60.0% 45.0% 52.5%
Total Count 20 20 40 20 20 40
% within OS 50.0% 50.0% 100.0% 50.0% 50.0% 100.0%
% within GROUP 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

Table 2: Showed the difference between both the drug groups with respect to the gravid status of the patients.

  GROUP Total GROUP Total
Labetalol in
Pre-Eclampsia
Methyl-Dopa in
Pre-Eclampsia
Labetalol in gestational hypertension Methyl-dopa in gestational hypertension
B/U B Count 16 15 31 15 15 30
% within B/U 51.6% 48.4% 100.0% 50.0% 50.0% 100.0%
% within GROUP 80.0% 75.0% 77.5% 75.0% 75.0% 75.0%
U Count 4 5 9 5 5 10
% within B/U 44.4% 55.6% 100.0% 50.0% 50.0% 100.0%
% within GROUP 20.0% 25.0% 22.5% 25.0% 25.0% 25.0%
Total Count 20 20 40 20 20 40
% within B/U 50.0% 50.0% 100.0% 50.0% 50.0% 100.0%
% within GROUP 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

Table 3: Shows that the percentage of Booked OR Unbooked (B/U) value of both drug groups.

    GROUP N Mean± SD t df P VALUE
Hypertension systolic fall in 48 hrs LABETELOL 20 9 ± 2.714 6.119 38 <0.001
  METHYL-DOPA 20 3.5±2.965      
diastolic fall in 48 hrs LABETELOL 20 6.7±2.849 3.976 38 <0.001
  METHYL-DOPA 20 3.6±2.01      
fall by 5th day systolic LABETELOL 20 16.2±3.548 6.119 38 <0.001
  METHYL-DOPA 20 8.3±4.555      
fall by 5th day diastolic LABETELOL 20 11.9±3.463 5.851 38 <0.001
  METHYL-DOPA 20 5.9±3.007      
Pre-Eclampsia systolic fall in 48 hrs LABETELOL 20 8.7±4.414 6.743 25.285 <0.001
  METHYL-DOPA 20 1.5±1.821      
diastolic fall in 48 hrs LABETELOL 20 7.2±4.561 4.366 28.29 <0.001
  METHYL-DOPA 20 2.2±2.331      
fall by 5th day systolic LABETELOL 20 16.8±5.288 5.81 38 <0.001
  METHYL-DOPA 20 8.3±3.854      
fall by 5th day diastolic LABETELOL 20 13.2±4.607 5.167 38 <0.001
  METHYL-DOPA 20 6.6±3.378      

Table 4: Comparison of Blood Pressure control among the two groups.

CATEGORY GROUP N Mean±SD t df Sig. (2-tailed)
Hypertension TDPD LABETELOL 20 500±189.181 -3.853 28.046 0.001
METHYL-DOPA 20 862.5±375.876      
Pre-eclampsia TDPD LABETELOL 20 480±188.065 -3.742 25.922 0.001
METHYL-DOPA 20 875±433.013      

Table 5: Depicts the mean Drug Dosage (TDPD-total dose per day) of patients receiving the drugs.

  CATEGORY GROUP N Mean SD t df Sig. (2-tailed)
Hypertension prolongation of pregnancy LABETELOL 20 14.4days 4.489 2.977 38 0.005
METHYL-DOPA 20 10.3days 4.219      
Pre-Eclampsia prolongation of pregnancy LABETELOL 20 13.3days 3.511 0.798 38 0.43
METHYL-DOPA 20 12.25days 4.723      

Table 6: Showed the Prolongation of Pregnancy (in days) in both drug groups.

CATEGORY GROUP N Mean ± SD t df Sig. (2-tailed)
Pre-Eclampsia Birth Weight LABETELOL 20 2.56±  0.213739 0.516 23.549 0.61
METHYL-DOPA 20 2.635±0.613253      
Hypertension Birth Weight LABETELOL 20 2.606±0.2523 0.445 26.704 0.66
METHYL-DOPA 20 2.545±0.5482      

Table 7: Showed the Birth Weight of child by the patient in both drug groups.

CATEGORY GROUP N Mean ± SD t df Sig. (2-tailed)
Pre-Eclampsia APGAR 5 min LABETELOL 20 7.55± 1.538 -0.673 38 0.505
METHYL-DOPA 20 7.85±1.268      
Hypertension APGAR 5 min LABETELOL 20 8±1.451 0.751 38 0.66
METHYL-DOPA 20 7.65±1.496      

Table 8: Describes the 5 Minute APGAR Scores in two groups.

Group Statistics
  GROUP N Mean Std. Deviation Std. Error Mean
NICU Labetelol 40 0.80 1.884 0.298
Methyl-dopa 40 1.50 3.581 0.566

Table 9: Showed the statistical values of NICU Stay in both groups.

Particulars Group Total Group Total
Labetalol in
pre-eclampsia
Methyl-dopa
in pre-eclampsia
labetalol in
gestational hypertension
methyl-dopa in
gestational hypertension
Neonatal morbidity Hyperbilirubinemia Count 5 4 9 4 3 7
% within neonatal morbidity 55.6% 44.4% 100.0% 57.1% 42.9% 100.0%
% within GROUP 25.0% 20.0% 22.5% 20.0% 15.0% 17.5%
Meconeum aspiration syndrome Count 1 1 2 1 0 1
% within neonatal morbidity 50.0% 50.0% 100.0% 100.0% 0.0% 100.0%
% within GROUP 5.0% 5.0% 5.0% 5.0% 0.0% 2.5%
Nil Count 12 12 24 13 14 27

Table 10: Depicts the Neonatal Morbidity of two drug groups.

Discussion

Most countries saw a decline in the rates of pregnancy hypertension and/or pre-eclampsia over time. This was an unexpected result, since factors thought to be positively associated with pregnancy hypertension such as pre-pregnancy overweight and obesity, diabetes, multiple births, and maternal age are generally recognised and associated with reduced rates of pregnancy hypertension [26]. Hypertensive disorders of pregnancy are one of the major causes of maternal and foetal mortality and morbidity and as long as its exact cause is unknown, its prophylaxis will be uncertain.Many drugs have been used in the management of hypertensive disorders in pregnancy. Variability in the age, parity, chronic disease, smoking and multiple birth distributions will also influence the baseline rates of pregnancy hypertension and preeclampsia. Study conducted by Verma et al. [26] states that adverse events observed were lower in the labetalol treated group compared to the methyldopa group. In a study by El-Qarmalawi et al. [23] patients receiving methyldopa complained of side-effects such as drowsiness (22.2%), headache (14.8%), nasal congestion (7.4%), postural hypotension (5.6%). 96 patients in labetalol group complained of dyspnoea, no other side-effects were noticed. Trends in these factors have been proposed as possible explanations for the increase in pregnancy hypertension and pre-eclampsia rates reported for the entire USA from 1987 to 1998 (although the rates plateaued from 1999 to 2004) [27]. While advanced maternal age and obesity are more common, the magnitude of risk is lower (less than double) [28].

The mean drug dosage required by labetalol was (500 ± 189.181) in hypertensive women and 480 ± 188.065 for pre-eclamptic women in comparison methyl dopa was required in higher doses, 862.5 ± 375.876 for hypertensive women and 875 ± 433.013 for pre-eclamptic women illustrating that methyl dopa requires higher doses to achieve clinical efficacy (Table 5). Out of the 40 women on labetalol 8 (20%) underwent caesarean section and the rest 32 (80%) underwent vaginal delivery. In the methyl dopa group 12 (30%) underwent caesarean section the rest 28 (70%) underwent vaginal delivery effectively proving that either of these drugs are not directly related to the mode of delivery how-ever the number of inductions was very high 50% and 47.5% in labetalol and methyl dopa respectively. The indications for termination of pregnancy by caesarean section in either drug groups were varied, obstetric indications such as occipito posterior, cervical dystocia or foetal indications such as foetal distress, severe IUGR with altered Doppler parameters, severe oligohydramnios, PROM, meconium staining of the liquor sometimes existing simultaneously. However these indications did not directly attribute to the usage of either drug rendering the above graphical values statistically non-significant.

In our study, the mean age of methyldopa group was 25.95 ± 3.94 years and 26.65 ± 3.73 years in Labetalol group. Similarly, Verma et al. [26] conducted the study and mentioned the age distribution showed maximum patients between 19-24 years in both groups (64.44% in methyldopa group and 57.77% in labetalol group) and there was no significant difference in age distribution in both groups. Most common age group is in contrast to the findings of a large database study wherein there was a linear relationship between age and incidence of pregnancy induced hypertension [29]. In the present study, about 32.5% of the pregnant women in Methyldopa group and 37.5% in Labetalol group were primigravidae. The rest of the patients were multigravidae. However the percentage of primigravidae is greater in most other studies where the prevalence of primigravidae was 50% or above [30,31].

There was a fall of 40% after 48 hours in patients with urine albumin of 2+ and 15% fall of urine albumin 3+ recorded on the day of admission with labetalol group in comparison with fall of 5% in patients with 2+ urine albumin and no fall in 3+ urine albumin levels from the day of admission to 48 hours of methyl dopa therapy. This demonstrates that labetalol improves the renal function better however other essential aspects of renal function such as blood urea and serum creatinine were not included in this study rendering the evaluation of these drugs on renal function incomplete.

Labetalol is an effective antihypertensive which decreases both systolic and diastolic BP in pregnancy induced hypertension was proved earlier. About 55% of the methyldopa group received nifedepine and phenobarbitonewhere as only 22.5% of labetalol group received inj labetalol and phenobarbitone showing that methyl dopa requires additional drugs BP management than labetalol. In our study clearly exhibit that labetalol is a better drug in effectively reducing the BP of the patients and then maintain optimal BP levels (Table 4). Similarly, Cruickshank et al. [32] observed that Labetalol did control the blood pressure in 45 of the 51 treated women (88%) within 24 hrs. It is interesting that several other workers have found similar response rates - Lardoux’s group 82%, CA Michael 92% [33,34]. Marked fall of both systolic and diastolic pressure generally between 24 and 48 hours from the start of using methyldopa was noticed by Hans and Kopelman [35]. The only limiting factor in use of labetalol is economic constraints among rural population of India. According to Brunton et al. [36] stated that labetalol provides more efficient control of BP than methyldopa in the treatment of mild hypertension in pregnancy which was also corroborated in our present study and the present study conluded that labetalol is more advantageous than methyldopa in terms of better and quicker control of blood pressure.

There were a total of 3 neonatl deaths, 2 (5%) in methyldopa group and 1 (2.5%) in labetalol group; controversaly, Plouin et al. [31] made a findings and our report were not in corroboration with his report. He also demonstrated that four still births in methyldopa group. In a study by Redman et al. [30] he found that two babies born to women assigned to labetalol died but no deaths were reported in methyldopa group. Methyldopa had side effects such as drowsiness, depression and dry mouth whereas labetalol had only nausea however on comparison between the two, the numbers were statistically insignificant. The chances of spontaneous onset of labour were greater in the labetalol group than in the methyldopa group. Those patients on labetalol, who required induction of labour, were noted to have a better Bishop score at the time of induction. The freedom from maternal and fetal sideeffects, the efficient hypotensive action and consequent improved perinatal mortality in a condition usually accompanied by high fetal loss, indicate that labetalol is suitable for use during pregnancy. The observation made by El-Qarmalawi et al. [23] suggest higher incidence of spontaneous onset of labour in the labetalol groupand Lamming and Symonds [25] reported a higher incidence of spontaneous labour in the labetalol group.

Conclusion

The present study confirms the previous findings that labetalol is an effective and safe drug for use quicker in achieving adequate in the control of blood pressure in pregnancy-induced hypertension. The low incidence of maternal and foetal side-effects together with the excellent perinatal outcome in a condition usually accompanied by a high maternal and foetal mortality and morbidity confirms its suitability for use during pregnancy. Unlike other antihypertensive drugs labetalol reduces peripheral resistance without significantly reducing maternal cardiac output and pulse rate. This may be an additional factor in maintaining adequate placental perfusion and therefore foetal oxygenation in the treatment of pregnancy hypertension with labetalol. The only regulating factor in use of labetalol is economic constraints among rural population of India.

Acknowledgements

The authors thanks the authorities for providing the necessary supports and technical facilities in the Yenepoya Medical College and Teaching Hospital and also thank the subjects who voluntarily take part in thisstudy.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11922
  • [From(publication date):
    September-2014 - Jun 22, 2017]
  • Breakdown by view type
  • HTML page views : 8125
  • PDF downloads :3797
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords